ArticleThe Journal of infectious diseases2022
Medically Attended Illness due to Respiratory Syncytial Virus Infection Among Infants Born in the United States Between 2016 and 2020.
Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed.
- Epidemiology and economic burden of hospitalizations attributable to Respiratory Syncytial Virus (RSV) infection among infants in France, 2016 to 2023 - EPIBREATHE study.BMC infectious diseases · 2025Article
- Recommendation for use of a long-acting monoclonal antibody to prevent respiratory syncytial virus infection in infants and young children.Clinical and experimental pediatrics · 2025Article
- Optimizing Timing for Respiratory Syncytial Virus Prevention Interventions for Infants.JAMA network open · 2025Article
- Article
- Inpatient service utilization amongst infants diagnosed with Respiratory Syncytial Virus infection (RSV) in the United States.PloS one · 2025Observational
- Inpatient Burden of Respiratory Syncytial Virus Infection and Influenza in Children Younger Than 5 Years in Japan, 2011-2022: A Database Study.Influenza and other respiratory viruses · 2024Article
- Healthcare resource utilisation and costs in infants with confirmed respiratory syncytial virus infections: a national population cohort study.BMC infectious diseases · 2024Article
- Article
- Cost-Effectiveness Analysis of Maternal Respiratory Syncytial Virus Vaccine in Protecting Infants from RSV Infection in Japan.Infectious diseases and therapy · 2024Article
- Risk Analysis of Respiratory Syncytial Virus Among Infants in the United States by Birth Month.Journal of the Pediatric Infectious Diseases Society · 2024Article
- All Infants Are at Risk of Developing Medically Attended Respiratory Syncytial Virus Lower Respiratory Tract Infection and Deserve Protection.The Journal of infectious diseases · 2022Article
- Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States.The Journal of infectious diseases · 2022Article
- The Burden of Respiratory Syncytial Virus Lower Respiratory Tract Disease in Infants in the United States: A Synthesis.The Journal of infectious diseases · 2022Article
- Association of citrulline concentration at birth with lower respiratory tract infection in infancy: Findings from a multi-site birth cohort study.Frontiers in pediatrics · 2022Article
Corrections and comments
- Erratum issued
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is a leading cause of infant hospitalization in the United States. Preterm infants and those with select comorbidities are at highest risk of RSV-related complications. However, morbidity due to RSV infection is not confined to high-risk infants. We estimated the burden of medically attended (MA) RSV-associated lower respiratory tract infection (LRTI) among infants in the United States.
methodsWe analyzed commercial (MarketScan Commercial [MSC], Optum Clinformatics [OC]), and Medicaid (MarketScan Medicaid [MSM]) insurance claims data for infants born between April 2016 and February 2020. Using both specific and sensitive definitions of MA RSV LRTI, we estimated the burden of MA RSV LRTI during infants' first RSV season, stratified by gestational age, comorbidity status, and highest level of medical care associated with the MA RSV LRTI diagnosis.
resultsAccording to the specific definition 75.0% (MSC), 78.6% (MSM), and 79.6% (OC) of MA RSV LRTI events during infants' first RSV season occurred among term infants without known comorbidities.
conclusionsTerm infants without known comorbidities account for up to 80% of the MA RSV LRTI burden in the United States during infants' first RSV season. Future prevention efforts should consider all infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.